Birchview Capital, LP Inhibrx, Inc. Transaction History

Birchview Capital, LP

  • $108 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$32.76 - $39.56 $720,720 - $870,320
-22,000 Reduced 31.23%
48,448 $1.69 Million
Q2 2022

Aug 12, 2022
BUY
$8.52 - $25.26 $170,400 - $505,200
20,000 Added 39.64%
70,448 $800,000
Q1 2022

May 13, 2022
BUY
$19.89 - $43.18 $207,810 - $451,144
10,448 Added 26.12%
50,448 $1.12 Million
Q4 2021

Feb 14, 2022
BUY
$26.75 - $46.02 $1.07 Million - $1.84 Million
40,000 New
40,000 $1.75 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $550M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Birchview Capital, LP Portfolio

Follow Birchview Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email